Division of Dermatology, McGill University, Montreal, QC, Canada.
Brunswick Dermatology Center, Fredericton, NB, Canada
Skin Therapy Lett. 2022 Sep;27(5):1-6.
Extracorporeal photopheresis (ECP) is an immunomodulatory therapy that has been used for over 35 years to treat numerous conditions. ECP was initially approved by the US FDA in 1988 for the treatment of Sézary syndrome, a leukemic form of cutaneous T-cell lymphoma (CTCL). Although CTCL remains the only FDA-approved indication, ECP has since been used off-label for numerous other conditions, including graft-versus-host disease (GvHD), systemic sclerosis, autoimmune bullous dermatoses, Crohn's disease, and prevention of solid organ transplant rejection. In Canada, ECP is mainly used to treat CTCL, acute and chronic GvHD, and in some instances systemic sclerosis. Herein, we review the current concepts regarding ECP mechanism of action, treatment considerations and protocols, and efficacy.
体外光分离术（ECP）是一种免疫调节疗法，已经使用了 35 多年来治疗多种疾病。ECP 最初于 1988 年获得美国 FDA 的批准，用于治疗蕈样肉芽肿，一种皮肤 T 细胞淋巴瘤（CTCL）的白血病形式。尽管 CTCL 仍然是唯一获得 FDA 批准的适应症，但 ECP 此后已被用于治疗许多其他疾病，包括移植物抗宿主病（GvHD）、系统性硬化症、自身免疫性大疱性皮肤病、克罗恩病和预防实体器官移植排斥反应。在加拿大，ECP 主要用于治疗 CTCL、急性和慢性 GvHD，在某些情况下还用于治疗系统性硬化症。在此，我们回顾了 ECP 作用机制、治疗注意事项和方案以及疗效的当前概念。
